AKT1 and neoplasm: We previously demonstrated that GFW could sensitize cisplatin-resistant SKOV3/DDP cells by inhibiting the protein level and function of P-glycoprotein (P-gp) and by inactivating the PI3K/AKT/mTOR pathway; in the resistant SKOV3/DDP xenograft tumour mice, GFW could enhance anticancer efficacy of cisplatin and paclitaxel without any mouse deaths during a 21-day administration at a dose of 4 g·kg− 1·d− 1 [36].